Fate Therapeutics, Inc.FATENASDAQ
Loading
Operating Expenses Over TimeContracting
Percentile Rank79
3Y CAGR-28.7%
5Y CAGR+33.1%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
-28.7%/yr
vs +52.7%/yr prior
5Y CAGR
+33.1%/yr
Recent deceleration
Acceleration
-81.5pp
Decelerating
Percentile
P79
Within normal range
vs 5Y Ago
4.2x
Strong expansion
Streak
1 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $141.45M | -36.8% |
| 2024 | $223.91M | +131.2% |
| 2023 | $96.86M | -75.2% |
| 2022 | $390.93M | +46.4% |
| 2021 | $266.99M | +687.7% |
| 2020 | $33.90M | -69.6% |
| 2019 | $111.41M | +55.1% |
| 2018 | $71.83M | +55.4% |
| 2017 | $46.23M | +27.1% |
| 2016 | $36.37M | - |